FALCIMEF TAB is a WHO-recommended Artemisinin-based Combination Therapy (ACT) formulation containing Artemether 80 mg and Lumefantrine 480 mg per tablet. This dual-drug combination is designed for the effective and rapid treatment of uncomplicated malaria caused by Plasmodium falciparum, including strains resistant to other antimalarial agents.
Artemether, a semi-synthetic derivative of artemisinin, rapidly reduces the parasite biomass by disrupting parasite membranes and inducing oxidative damage within infected erythrocytes. Its fast onset of action ensures quick symptomatic relief, particularly in fever and parasitemia.
Lumefantrine complements Artemether by acting on the residual parasites, providing a longer half-life and sustained antimalarial effect. It interferes with the heme detoxification process essential for parasite survival. The synergistic action of these two agents ensures:
Rapid parasite clearance
Prevention of recrudescence
Low resistance potential
This makes FALCIMEF TAB ideal for use in endemic regions, travel medicine, and public health malaria control programs.
FALCIMEF TAB stands as a reliable and effective antimalarial combination developed to meet the needs of modern malaria treatment and public health programs. Manufactured by BluepillExpress, it represents our commitment to quality, efficacy, and global health. Whether for national procurement, institutional supply, or private market expansion, FALCIMEF TAB is a trusted solution backed by science and supported by international regulatory standards.
Description provided by bluepill express.
FIEO Registered
Export Ready
